Organobismuth compounds: Activity against Helicobacter pylori

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 2, 1999, Pages 135-137

  Dahlgren, A ^b   Glogard C ^b   Gammelsaether M ^b   Aasen, A J ^b   Klaveness, J ^b   Berdal, B P ^b   Bergan, Tom ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

Antibacterial activity; Helicobacter pylori; Organobismuth compounds; Peptic ulcer

Indexed keywords

AMPICILLIN; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; DOXYCYCLINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; ERADICATION THERAPY; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; NEUROTOXICITY; PEPTIC ULCER; PRIORITY JOURNAL; TREATMENT PLANNING;

HELICOBACTER PYLORI;

EID: 1342336801     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529950172970     Document Type: Article

References (22)

1. van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infections. A review of the world literature. Helicobacter 1996;1:6-19.
2. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102:493-6.
3. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88:505-9.
4. Graham DY, de Boer WA, Tytgat GNJ. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-6.
5. Williamson R, Pipkin GA, Dixon JS, Wood JR. Approaches to the prevention and treatment of Helicobacter pylori infection. Yale J Biol Med 1997;70:7-18.
6. Lerang F, Moum B, Ragnhildstveit E. A comparison between omeprazole-based triple therapy and bismuth based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Int J Gastroenterol 1997;92:1-6.
7. Berstad A, Hatlebakk JG, Wilhelmsen I. Follow-up on 242 patients with peptic ulcer disease one year after eradication of Helicobacter pylori infection. Hepat Gastroenterol 1995;42: 655-9.
8. Marshall BJ. The use of bismuth in gastroenterology. Am J Gastroenterol 1991;86:16-23.
9. Slikkerveer A, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adv Drug Exp 1989;4:303-23.
10. Tillman LA, Drake FM, Dixon JS, Wood JR. Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol Ther 1996;10:459-67.
11. Berstad A, Olafsson S, Tefera S, Berstad K, Hundal Ø, Bergseth M, et al. Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. J Physiol Pharmacol 1996;47:31-49.
12. Rabasseda X, Mealy N, Castañer J. Ranitidine bismuth citrate. Drugs Future 1995;20:480-2.
13. Sun H, Li H, Sadler PJ. The biological and medicinal chemistry of bismuth. Chem Ber 1997;130:669-81.
14. Dittes V, Vogel E, Keppler BK. Overview on bismuth(III) and bismuth(V) complex with activity against Helicobacter pylori. Coord Chem Rev 1997;163:345-64.
15. Gløgård C, Dahlgren A, Aasen AJ, Klaveness J, Berdal B, Bergan T. Synthesis and antimicrobial activity of organic bismuth compounds. Int Agents J Antibiot Agents. In press.
16. Meyers AI, Temple DL, Haidukewych D, Mihelich ED. Oxazolines. XI. Synthesis of functionalized aromatic and aliphatic acids. A useful protecting group for carboxylic acids against Grignard and hydride reagents. J Org Chem 1974;39: 2787-93.
17. de Ketelaere RF, Delbeke FT, van der Kelen GP. Organo group VB chemistry. III. Synthesis and NMR spectra of some tertiary substituted arylstibines and arylbismuthines. J Organomet Chem 1971;30:365-8.
18. Matano Y, Kinoshita M, Suzuki H. Synthesis and reactions of some crowded triorganylbismuthines. Bull Chem Soc Jpn 1992; 65:3504-6.
19. Challenger F. XXVIII. Organo-derivatives of bismuth. J Chem Soc 1916;109:250-1.
20. Challenger F, Wilkinson JF. XVI. Organo-derivatives of bismuth. Part V. The stability of halogen, cyano-and thiocyanoderivatives of tertiary aromatic bismuthines. J Chem Soc 1922;121:91-104.
21. Stablers R, Campbell CJ, Clayton NM, Clitherow JW, Grinham CJ, Mc Colm AA, et al. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther 1993;7: 237-46.
22. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pyloric infection. Aliment Pharmacol Ther 1997;11 Suppl 1:27-33.